2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.139 (Poster) Cardiac Events Following Concurrent Chemotherapy and Radiation with Durvalumab Consolidation for Unresectable Non-Metastatic Non-Small Cell Lung Cancer

PP01.139 (Poster) Cardiac Events Following Concurrent Chemotherapy and Radiation with Durvalumab Consolidation for Unresectable Non-Metastatic Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study focused on the occurrence of cardiac events (CEs) in patients with unresectable non-metastatic non-small cell lung cancer (NSCLC) who received concurrent chemotherapy and radiation followed by Durvalumab consolidation. It is known that immune-related adverse events (irAEs) are common with immune checkpoint inhibitors (ICIs), and immune-related cardiotoxicity can manifest as various cardiac conditions. The study aimed to quantify and characterize these CEs.<br /><br />The study retrospectively identified patients who received this treatment regimen at a large academic medical center between January 2017 and April 2021. Patient demographics, treatment history, cardiovascular comorbidities, laboratory results, and CEs occurring within 2-3 years of treatment were collected through chart review.<br /><br />The results showed that among 116 patients, 24% experienced CEs. The cardiac events included new/worsening arrhythmias, new/worsening cardiomyopathy, and new/worsening coronary artery disease. Patients who experienced CEs had received an average of 16.6 cycles of Durvalumab, while those who did not experience CEs had received an average of 15.4 cycles.<br /><br />The study concluded that cardiac events can occur in up to 25% of patients with locally advanced, unresectable NSCLC following exposure to concurrent chemoradiotherapy and Durvalumab. The next step is to perform multivariable logistic regression analysis to determine the association between the occurrences of CEs and cumulative exposure to chemotherapy, radiation, and immunotherapy.<br /><br />Additionally, the study plans to further analyze changes in coronary atherosclerotic plaque burden across CT scans with ICI exposure and correlate them with cardiac events. This will help in better understanding the mechanisms behind immune-related cardiotoxicity and potentially identify strategies for intervention and prevention.<br /><br />In summary, this study highlights the potential cardiac events associated with concurrent chemoradiotherapy and Durvalumab in patients with unresectable NSCLC. The findings emphasize the importance of long-term monitoring and intervention for cardiac toxicities in this patient population.

Asset Subtitle

Nikita Patel

Keywords

cardiac events

unresectable non-metastatic non-small cell lung cancer

concurrent chemotherapy

radiation

Durvalumab consolidation

immune-related adverse events

immune checkpoint inhibitors

immune-related cardiotoxicity

cardiovascular comorbidities

multivariable logistic regression analysis